((2-bromobenzyl)oxy)(tert-butyl)dimethylsilane | 94236-20-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ((2-bromobenzyl)oxy)(tert-butyl)dimethylsilane
• 英文别名: (2-bromophenyl)methoxytert-butyldimethylsilane；2-bromobenzyl tert-butyldimethylsilyl ether；2-bromo-1-(tert-butyldimethylsilyloxymethyl)benzene；(2-Bromobenzyloxy)tert-butyldimethylsilane；(2-bromophenyl)methoxy-tert-butyl-dimethylsilane
• CAS: 94236-20-1
• 化学式: C₁₃H₂₁BrOSi
• 分子量: 301.299
• InChiKey: FVIYZRQNZACNMT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.97
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  ((2-bromobenzyl)oxy)(tert-butyl)dimethylsilane 在 tris(dibenzylideneacetone)dipalladium(0) chloroform complex 盐酸 、 三苯基膦 作用下， 以 丙酮 、 甲苯 为溶剂， 反应 0.5h， 生成 5-[2-(tert-butyl)dimethylsilyloxymethyl-phenyl]-furan-2-yl-aldehyde
  参考文献：
  名称：

  Efficient synthesis of 5-aryl-2-vinylfurans by palladium catalyzed cross-coupling strategies

  摘要：

  The synthesis of substituted 5-aryl-2-furfurals from furfural by three alternative palladium cross coupling strategies are described. The resulting 5-aryl-2-furfurals were converted into their corresponding 5-aryl-2-vinylfurans in good yields by Wittig chemistry, (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(99)00817-5
• 作为产物：
  描述：

  2-溴苄醇 、 叔丁基二甲基氯硅烷 在 咪唑 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 以85%的产率得到((2-bromobenzyl)oxy)(tert-butyl)dimethylsilane
  参考文献：
  名称：

  基于量子化学计算的活细胞超分辨率成像自发闪烁荧光团的设计

  摘要：

  自发闪烁的荧光团是在生理条件下进行活细胞超分辨率成像的强大工具。在这里，我们证明了量子化学计算可以预测荧光团设计的关键参数。我们应用此方法开发了具有黄色荧光的自发闪烁荧光团，用于活细胞中微管的超分辨率成像。

  DOI：

  10.1039/d0cc05126h

文献信息

• POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF
  申请人：DE PERETTI Danielle

  公开号：US20110065727A1

  公开（公告）日：2011-03-17

  Compounds of formula (I): wherein R, R 1 , R 2 , R 3 , R 4 and X are as defined in the disclosure, or an acid addition salt thereof, and the therapeutic use and process of synthesis thereof.

  式（I）的化合物： 其中R、R1、R2、R3、R4和X如披露中所定义，或其酸盐，以及其治疗用途和合成过程。
• Macrocyclic MCL-1 inhibitors and methods of use
  申请人：AbbVie Inc.

  公开号：US20190055264A1

  公开（公告）日：2019-02-21

  The present disclosure provides for compounds of Formula (I) wherein A 2 , A 3 , A 4 , A 6 , A 7 , A 8 , A 15 , R A , R 5 , R 9 , R 10A , R 10B , R 11 , R 12 , R 13 , R 14 , R 16 , W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

  本公开提供了Formula (I)的化合物，其中A2、A3、A4、A6、A7、A8、A15、RA、R5、R9、R10A、R10B、R11、R12、R13、R14、R16、W、X和Y具有规范中定义的任何值，以及其药学上可接受的盐，可用作治疗疾病和病况的药物，包括癌症。还提供了包含Formula (I)化合物的药物组合物。
• [EN] BICYCLIC HETEROCYCLYL COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROCYCLYLE BICYCLIQUES ET LEURS UTILISATIONS
  申请人：REVOLUTION MEDICINES INC

  公开号：WO2020180770A1

  公开（公告）日：2020-09-10

  The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.

  本公开涉及SOS1的调节剂及其在治疗疾病中的应用。还公开了包含相同成分的药物组合物。
• Synthesis of Eight-Membered Lactones: Intermolecular [6+2] Cyclization of Amphoteric Molecules with Siloxy Alkynes
  作者：Wanxiang Zhao、Zhaobin Wang、Jianwei Sun

  DOI：10.1002/anie.201200513

  日期：2012.6.18

  That's about the size of it: The title molecules react with siloxy alkynes in the presence of a Brønsted acid to deliver medium‐sized lactones through a [6+2] cyclization (see scheme; TIPS=triisopropylsilyl). This process is the first intermolecular synthesis of such lactones and involves a sequence of several selective ring‐opening/ring‐closing events.

  大小差不多：标题分子在布朗斯台德酸的存在下与甲硅烷氧基炔烃反应，通过[6 + 2]环化反应输送中等大小的内酯（参见方案； TIPS =三异丙基甲硅烷基）。该过程是此类内酯的首次分子间合成，涉及一系列选择性开环/闭环事件。
• Calcium receptor antagonist
  申请人：——

  公开号：US20040006130A1

  公开（公告）日：2004-01-08

  A compound of the formula [I] 1 wherein R 1 is optionally substituted aryl group or optionally substituted heteroaryl group; R 2 is optionally substituted C 1-6 alkyl group, C 3-7 cycloalkyl group and the like; R 3 is hydrogen atom, C 1-6 alkyl group, hydroxyl group and the like; R 4 is hydrogen atom, C 1-6 alkyl group and the like; R 5 and R 6 are each C 1-6 alkyl group and the like; R 7 is optionally substituted aryl group or optionally substituted heteroaryl group; X 1 , X 2 and X 3 are each C 1-6 alkylene group and the like; and X 4 and X 5 are each a single bond, methylene group and the like, a salt thereof, a solvate thereof or a prodrug thereof, and a pharmaceutical composition containing the compound, particularly a calcium receptor antagonist and a therapeutic agent for osteoporosis, are provided. The compound of the present invention is useful as a therapeutic drug of diseases accompanied by abnormal calcium homeostasis, or osteoporosis, hypoparathyreosis, osteosarcoma, periodontal disease, bone fracture, steoarthrosis, chronic rheumatoid arthritis, Paget's disease, humoral hypercalcemia, autosomal dominant hypocalcemia and the like. In addition, an intermediate for the compound is provided.

  式为[I]的化合物，其中R1是可选择取代的芳基或可选择取代的杂环基；R2是可选择取代的C1-6烷基、C3-7环烷基等；R3是氢原子、C1-6烷基、羟基等；R4是氢原子、C1-6烷基等；R5和R6分别是C1-6烷基等；R7是可选择取代的芳基或可选择取代的杂环基；X1、X2和X3分别是C1-6亚烷基等；X4和X5分别是单键、亚甲基基团等，提供其盐、溶剂合物或前药，以及含有该化合物的药物组合物，特别是一种钙受体拮抗剂和治疗骨质疏松症的药物。本发明的化合物可用作伴有异常钙稳态或骨质疏松症、甲状旁腺功能减退症、骨肉瘤、牙周病、骨折、骨关节炎、慢性类风湿关节炎、帕盖特病、体液性高钙血症、常染色体显性低钙血症等疾病的治疗药物。此外，还提供了该化合物的中间体。